

hydrix[®]

**Improve
a billion
lives**





Growth through
medtech innovation

Building on 20 years of medtech product innovation



Sales & Distribution



Identifying and
distributing high
growth medtech
products

Product Innovation



Transforming ideas
into commercial
products



Venture Investment

Investing in
early-stage high
potential medical
device companies



Our strategic focus

**Improve
cardiovascular
disease (CVD)
management
& outcomes**

CVD is the

No 1

Cause of death globally

18million

Annual global
CVD related
deaths ¹

85%

CVD deaths
caused by
heart attacks
or stroke ¹

USD


\$1trillion_{est}

Cost and
burden to
government
and hospitals ²



2025 objective

Three or more
CVD devices
producing
+\$50m
revenues p.a.
in 2025



Key CVD markets include

Ambulatory Monitoring Devices³

\$3.8B

Global market
2020

Estimated 2027

\$6.7B

Interventional Devices⁴

\$17.5B

Global market
2020

Estimated 2027

\$26.8B

Cardiac Rhythm Management⁴

\$20.4B

Global market
2020

Estimated 2027

\$31.2B

Cardiovascular Surgery Devices⁴

\$1.9B

Global market
2020

Estimated 2027

\$2.1B



Realising our objective

Preparing for product launches in CVD market in CY22



Product 1

Implantable Monitoring Device

AngelMed Guardian

FDA approved implantable continuous heart monitor

- 45% of heart attacks are silent
- <1 hour surgery, like a pacemaker implant
- Significantly reduces false positive hospital visits



Product 2

Cardiovascular Surgery Device

Phyzhon FFR

Coronary guidewire with integrated pressure sensor

- Improve stent placement procedures
- Better patient experience
- Reduces treatment time

Small percentage market capture can deliver A\$50m+ revenues p.a.




Future product expansion

We are evaluating several new opportunities to build on our product portfolio



News flow

Progressing towards first commercial product sales




Despite COVID causing ‘months’ of delays during the past 12 months we are progressing towards significant key milestones in the coming months

- Appoint additional Non-Executive Director (announced October 26)
- First AngelMed Guardian sales in New Zealand (WAND registration complete)
- First AngelMed Guardian implants in Australia (Special Access Scheme)
- Commence First-in-Human Trials of Phyzhon cardiac catheter guidewire
- AngelMed Guardian TGA (AUS) regulatory & reimbursement approvals
- Appointments of APAC sub-distributors for AngelMed Guardian
- AngelMed Guardian HSA (SNG) regulatory approval
- Hydrix Venture portfolio revaluations



Driving value creation

Fast emerging global medtech product company



Changing the mix of Hydrix revenues



Summary

Building a global medtech product company by 2025

World class
team
focused on
improving
**a billion
lives**

Products
sales into the
**US \$70B
CVD market**
commencing
CY2022

Board
and
management
with a
**proven
track record**



**Making
the world
a better
place**





Disclaimer

This presentation has been prepared by Hydrix Limited (the “Company” or “Hydrix”). This presentation is being provided to investors for the sole purpose of providing preliminary background financial and other information to enable recipients to review the business activities of the Company. The document is not intended to constitute an invitation or an inducement to engage in any investment activity. The presentation is not intended to constitute investment advice and should not be relied upon as such. This document is not intended as an offer or recommendation with respect to the purchase or sale of any securities in the Company.

The content and graphical illustrations contained in the presentation are provided for information purposes and should not be relied upon to form any investment decisions or to predict future performance. The Company is wholly reliant upon third parties for the accuracy and completeness of the information in the presentation and has no duty of care owed to you in relation to such information. Although the information expressed is provided in good faith and the Company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved. Important factors that could cause actual results to differ materially from those included in the forward-looking statements include amongst others, unforeseen delays in product development, the timing and extent of any changes in the associated technology and the ability of the Company to meet its stated business goals.

Prospective investors should make their own independent evaluation of an investment in the Company or seek advice from their financial adviser, accountant, lawyer, stockbroker or other professional adviser before making any investment decision. Nothing in this presentation should be construed as financial product advice, whether personal or general, for the purposes of Section 766B of the Corporations Act, or otherwise. This presentation does not amount to, involve or imply a recommendation or a statement of opinion in respect of whether to buy, sell or hold a financial product.

Neither Hydrix nor any of its or their associates or any of the Company’s directors’ (Hydrix Group) shall have any liability whatsoever for: (a) investment advice; (b) a recommendation to enter into any transaction or strategy; (c) advice that a transaction or strategy is suitable or appropriate; (d) the primary basis for any investment decision; (e) a representation, warranty, guarantee with respect to the legal, accounting, tax or other implications of any transaction or strategy; or (f) to cause the Hydrix Group to be an advisor or fiduciary of any recipient of this report or other third party. None of the Hydrix Group shall be responsible for or have any liability to you for losses or damages (whether consequential, incidental or otherwise) arising in any way for errors or omissions in, or the use of or reliance upon the information contained in this document. To the greatest extent permitted by law, we exclude all conditions and warranties that might otherwise be implied by law with respect to the document, whether by operation of law, statute or otherwise, including as to their accuracy, completeness or fitness for purpose. Unauthorised copying of this document is prohibited.